ANAVEX LIFE SCIENCES CORP.
Anavex Life Sciences is a clinical-stage biopharmaceutical company based in New York, New York. It develops potential treatments for people with central nervous system disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia and rare diseases such as Rett syndrome. Anavex applies precision medicine to drug development and analyzes genomic data from clinical trials to identify biomarkers. Its research and development pipeline includes ANAVEX®2-73, also known as blarcamesine, which is in clinical development for diseases including Alzheimer’s, Parkinson’s and Rett syndrome. The company is also developing ANAVEX®3-71, an oral drug candidate studied in a clinical trial for schizophrenia, alongside other compounds in clinical and preclinical development. Anavex has received research grants for studies of its drug candidates.
No enriched coverage for $AVXL in the last 7 days.
No SEC Form 4 filings for $AVXL in the last 30 days.
See all $AVXL insider activity →Anavex Life Sciences (AVXL) named Terrie Kellmeyer as its permanent CEO and Board member. Kellmeyer had been interim CEO and previously held senior roles at other companies.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy
Anavex Life Sciences (AVXL) reconstituted its board committees after three directors resigned, citing strategic differences. Claus van der Velden, Peter Donhauser, and Axel Paeger were appointed as chairs of the Audit, Compensation, and Nominating & Corporate Governance committees, respectively. Analysts have a mixed outlook, with a Buy rating and $20 target, while TipRanks' AI Analyst rates it Neutral due to financial and technical concerns.
Recent AVXL coverage spans financial news, corporate actions and regulation.
The leadership transition may cause modest market reaction as investors reassess the company's strategic direction.
Leadership transition to a seasoned biotech executive.
Governance shake‑up may raise uncertainty and pressure on the stock.
Board turnover tied to strategy misalignment can raise governance and execution concerns, at least near term.
The study completions provide key pharmacology data, likely supporting future regulatory filings and may improve market perception.
AlphAI scores every news story that mentions AVXL with an AI model for sentiment and relevance, and aggregates insider trades from ANAVEX LIFE SCIENCES CORP.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Anavex Life Sciences (AVXL) named Terrie Kellmeyer as its permanent CEO and Board member. Kellmeyer had been interim CEO and previously held senior roles at other companies.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EXHIBIT 99.1 Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors Seasoned biopharmaceutical executive with more than 30 years of leadership experience spanning clinical development, regulatory strategy
Anavex Life Sciences (AVXL) reconstituted its board committees after three directors resigned, citing strategic differences. Claus van der Velden, Peter Donhauser, and Axel Paeger were appointed as chairs of the Audit, Compensation, and Nominating & Corporate Governance committees, respectively. Analysts have a mixed outlook, with a Buy rating and $20 target, while TipRanks' AI Analyst rates it Neutral due to financial and technical concerns.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2026, each of Dr. Jiong Ma, Mr. Gautam Patel and Dr. Adrian Senderowicz resigned from the Board of Director
Anavex completed ADME and DDI studies for blarcamesine, with 65 and 8 healthy volunteers respectively, and no serious adverse events reported. The FDA cleared the IND for Fragile X syndrome, and a meeting is scheduled to discuss adding pediatric participants to the Phase 3 Rett syndrome trial.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies Clinical conduct of both blarcamesine (ANAVEX®2-73) studies in healthy volunteers is now complete, data are expected to support clinical pharmacology character
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome Anavex now has open INDs in all three core indications: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome Phase 2a study will evaluate the safety, tolerability and ph
Anavex Life Sciences (AVXL) received FDA clearance to proceed with a Phase 2a study of blarcamesine for Fragile X syndrome, a condition with no FDA-approved treatments. The study will evaluate the drug's safety, tolerability, and pharmacokinetics in about 60 adult males.
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.01 Changes in Control of Registrant. As further described under Item 5.07 of this Current Report on Form 8-K, Anavex Life Sciences Corp. (“Anavex” or the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on September 24, 2026. The election of t
Anavex Life Sciences (AVXL) is advancing Alzheimer's Phase 3 planning with the FDA and reported $118.3M in cash, extending its runway into fiscal 2028. The company is focusing on blarcamesine for Alzheimer's, Rett syndrome, and Fragile X syndrome. It expects to submit a Fragile X IND in September and seeks FDA agreement to include pediatric patients in its Rett syndrome Phase 3 trial.
